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Background: We sought to determine the impact of treatment flexibility on clinical outcomes in either a
corifollitropin alfa or recombinant follicle-stimulating hormone (rFSH) protocol.
Methods: Post hoc analysis of a prospective, multicenter, randomized, double-blind, double-dummy non-inferiority
clinical trial (Engage). Efficacy outcomes were assessed on patients from the Engage trial who started treatment on
menstrual cycle day 2 versus menstrual cycle day 3, patients who received rFSH step-down or fixed-dose rFSH,
patients who received rFSH on the day of human chorionic gonadotropin (hCG) compared with those who did not,
and patients who received hCG when the criterion was reached versus those with a 1-day delay.
Results: The effect of each of the treatment flexibility options on ongoing pregnancy rate was not significant. The
estimated difference (95% confidence interval) in ongoing pregnancy rate was -4.3% (-9.4%, 0.8%) for patients who
started ovarian stimulation on cycle day 2 versus day 3, 1.8% (-4.1%, 7.6%) for patients who received hCG on the
day the hCG criterion was met versus 1 day after, 3.2% (-2.1%, 8.6%) for patients who received rFSH on the day of
hCG administration versus those who did not, and -5.8% (-13.0%, 1.4%) for patients who received a reduced versus
fixed-dose of rFSH from day 8.
Conclusions: Treatment flexibility of ovarian stimulation does not substantially affect the clinical outcome in
patients’ treatment following initiation of ovarian stimulation with either corifollitropin alfa or with daily rFSH in a
gonadotropin-releasing hormone antagonist protocol.
Trial registration: Trial was registered under ClinicalTrials.gov identifier NCT00696800.
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Corifollitropin alfa, a novel hybrid molecule with
sustained follicle-stimulating activity, is a recombinant
molecule constructed by coupling the carboxy terminal
peptide of the β-subunit of human chorionic gonado-
tropin (hCG) to the follicle-stimulating hormone (FSH) β-
subunit [1]. Due to its pharmacokinetic profile, a single
injection of corifollitropin alfa can initiate and sustain
multi-follicular growth by maintaining FSH levels above
the threshold required for the first 7 days of controlled* Correspondence: aleader@conceive.ca
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reproduction in any medium, provided the orovarian stimulation (COS) for in vitro fertilization (IVF)
and can replace seven daily injections of recombinant FSH
(rFSH) [1,2].
The efficacy and safety of corifollitropin alfa have been
evaluated in the Engage [3], Ensure [4], and Trust [5]
trials. In the Engage trial, ongoing pregnancy rates were
assessed in 1506 treated patients after one injection of
150 μg corifollitropin alfa during the first 7 days of stimu-
lation and compared with seven daily injections of 200 IU
human rFSH using a standard gonadotropin-releasing
hormone (GnRH) antagonist protocol in patients from
North America and Europe. Ongoing pregnancy rates of
38.9% for the corifollitropin alfa group and 38.1% for the
rFSH group were achieved, with an estimated non-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[CI], -3.9% to +5.7%) in favor of corifollitropin alfa [3].
Equivalent ongoing pregnancy rates by treatment were
independent of whether patients underwent IVF or intra-
cytoplasmic sperm injection (ICSI), had single or double
embryo transfer or embryo transfer on day 3 or day 5.
Within each continent there were no differences in the
ongoing pregnancy rate and live-birth rate between the
two treatment groups; however, between continents, the
ongoing pregnancy rate and live-birth rate were conside-
rably higher in North America than in Europe [6].
The new treatment option with corifollitropin alfa in a
GnRH antagonist protocol is simpler and more conveni-
ent than daily rFSH treatment for patients undergoing
assisted reproductive technology (ART) [1,3]. However,
there is a perception that there is a loss of flexibility with
the corifollitropin alfa treatment option. Flexibility op-
tions of clinical importance include: (i) the start day of
stimulation, (ii) the option of a 24-h delay in administra-
tion of hCG to induce final oocyte maturation, (iii) the
option of receiving rFSH on the day of hCG, and (iv) the
option of a step-down or fixed-dose of rFSH from day 8.
These options were allowed in the Engage trial. In this
post hoc analysis of the data from the Engage trial we
report the impact of treatment flexibility on clinical out-
comes in either a corifollitropin alfa or an rFSH regimen.
Methods
Study design
The Engage trial was a prospective, multicenter, rando-
mized, double-blind, double-dummy non-inferiority cli-
nical trial. The details of the Engage trial have been
published [3] and are summarized below.
The trial was conducted in accordance with principles
of Good Clinical Practice and was approved by the
appropriate institutional review boards and regulatory
agencies. Written informed consent was provided by all
subjects.
Patients were treated with either a single subcutaneous
(SC) injection of 150 μg (0.5 mL) corifollitropin alfa (N.V.
Organon, The Netherlands) or daily 200 IU rFSH (folli-
tropin beta, Follistim AQ Cartridge, N.V. Organon) from
day 2 or day 3 of menses (stimulation day 1) for the first
7 days, followed by daily SC injections of rFSH ≤200 IU
from stimulation day 8 up to and including the day of
hCG administration, depending on the follicular response
and at the discretion of the investigator.
Depending on the ovarian response on stimulation day
8, either a maximal daily dose of 200 IU rFSH or a
reduced dose (step-down) was allowed, at the discretion
of the investigator, in an effort to reduce the risk of
severe ovarian hyperstimulation syndrome (OHSS).
Similarly, a reduction in the rFSH dose was also allowed
from stimulation day 6 onward if too high an ovarianresponse was noted. At the discretion of the investigator,
rFSH administration could be withheld for a maximum of
3 days (coasting) up to and including the day of hCG ad-
ministration. When no follicles ≥11 mm were visible on
ultrasound scan before injection on stimulation day 8, the
cycle was cancelled due to insufficient ovarian response.
To prevent premature luteinizing hormone surges, the
GnRH antagonist ganirelix 0.25 mg (Ganirelix Acetate
Injection, N.V. Organon) was administered once daily
SC starting on stimulation day 5 up to and including the
day of hCG. Urinary hCG 10,000 IU or 5000 IU (in the
case of too high an ovarian response) was administered
to induce final oocyte maturation as soon as at least
three follicles ≥17 mm were observed by ultrasound
scan, or on the next day.
Approximately 34–36 h after hCG injection, oocyte
retrieval followed by standard IVF or ICSI was performed.
Embryo quality was evaluated for all available embryos on
day 3 of culture. Good-quality embryos were those graded
as grade 1 (6–10 cells, no fragmentation, and equal blas-
tomere size) or grade 2 (up to 20% fragmentation). To
support implantation and early pregnancy, luteal phase
support with progesterone (at least 600 mg/d vaginally or
at least 50 mg/d intramuscularly [IM]) was started on the
day of oocyte retrieval and continued for at least 6 weeks,
or either up to menses or a negative pregnancy test
performed at least 14 days after embryo transfer.
Setting
The trial was carried out in 34 different IVF centers, 20
in Europe and 14 in North America.
Participants
Women aged 18–36 years with a body weight from 60–
90 kg, a body mass index of 18–32 kg/m2, a menstrual
cycle length of 24–35 days and access to ejaculatory sperm
and an indication for COS before IVF or ICSI were eligible.
Variables
Duration of stimulation, number of follicles ≥11 mm on
day 8 and on day of hCG, estradiol levels on day 8 and
day of hCG, number of oocytes retrieved, number of
(good-quality) embryos obtained on day 3, cycle cancel-
lation rate, ongoing pregnancy rate (defined as presence
of at least one embryo with heart activity at least
10 weeks after embryo transfer as assessed by ultrasound
scan or Doppler, or confirmed by live birth), and inci-
dence of OHSS (data not shown) were assessed.
Statistical methods
This retrospective analysis compared four patient sub-
groups: (i) patients who started treatment on menstrual
cycle day 2 or day 3, (ii) patients who received hCG on
the day that the criterion for administration was reached
Leader et al. Reproductive Biology and Endocrinology 2013, 11:52 Page 3 of 8
http://www.rbej.com/content/11/1/52versus those with a 1-day delay in hCG administration,
(iii) patients who did or did not receive rFSH on the day
of hCG administration, and (iv) patients who received
step-down or fixed-dose rFSH from day 8. These flexibi-
lity options were chosen as they are of particular clinical
importance [3]. The data used in the current analyses re-
flect minor corrections to the previously published En-
gage trial data [3].
The first three subgroups (i-iii) include patients who
received hCG and for whom no rFSH dose was withheld
for one or more consecutive days including the day of
hCG (n = 1437; 716 patients in the corifollitropin alfa
group and 721 patients in the rFSH group). This set is
referred to as Analysis Set 1. The fourth patient sub-
group (iv) included patients who received hCG on or
after day 9 and for whom no rFSH dose was withheld
for one or more consecutive days from day 8 including
the day of hCG (n = 1056; 547 patients in the cori-
follitropin alfa group and 509 patients in the rFSH
group). This set is referred to as Analysis Set 2.
The impact of each of the four treatment options on
the ongoing pregnancy rate was assessed using a gene-
ralized linear model with binomial distribution, identity
link, and covariates. The model based on Analysis Set 1
(Model 1) includes separate factors (covariates) for the
three treatment flexibility options (i) cycle day 2, cycle
day 3, (ii) no delay, 1-day delay, and (iii) rFSH on day of
hCG, no rFSH on day of hCG. The model based on
Analysis Set 2 (Model 2) includes a factor for treatment
option iv (step-down rFSH, fixed-dose rFSH). Age, treat-
ment group (corifollitropin alfa, rFSH), and region (Europe,
North America) were added as covariates to both models.
Age is a well-known predictor of pregnancy and region
was associated with the chance of ongoing pregnancy in
the Engage trial [6]. Based on these models, risk differences
after adjusting for covariates were calculated for each of
the four treatment options. Interaction terms of treatment
group by each treatment flexibility option were added to
the models to explore the dependency of the treatment
flexibility options on treatment group with respect to their
impact on ongoing pregnancy rate.
Results
Patient baseline demographics
As might be expected, patient characteristics, including
mean age (30.3–31.9 years), weight (68.0–69.5 kg), body
mass index (24.7–25.3 kg/m2), and duration of infertility
(3.0–3.5 years), were similar across all subgroups regard-
less of treatment flexibility option (those who started
treatment on menstrual cycle day 2 or cycle day 3, who
received hCG as soon as the criterion was reached or
with 1-day delay, who did or did not receive rFSH on
day of hCG, and those who received step-down or fixed
dose rFSH).Patients who received a reduced (step-down) rFSH
dose had a higher ovarian reserve, as indicated by their
baseline antral follicle count (mean [SD], 13.8 [4.1] and
12.9 [3.9] with corifollitropin alfa and rFSH treatment,
respectively) than patients who received a fixed 200 IU
daily dose of rFSH (11.9 [4.5] and 11.8 [4.3], with cori-
follitropin alfa and rFSH treatment, respectively). The
antral follicle counts were similar in the other treatment
flexibility options.
In both treatment groups, a higher percentage of pa-
tients with a 1-day hCG delay were from North America
(76.6% and 73.3% for corifollitropin alfa and rFSH treat-
ment, respectively) than from Europe (23.4% and 26.7%
for corifollitropin alfa and rFSH treatment, respectively).
For the other treatment options, the percentage of
patients from North America and Europe were similar
across the subgroups and varied between 40% and 60%.
Main results
Start day of stimulation on day 2 or 3 of menses
The ovarian response was similar between patients who
started treatment on menstrual cycle day 2 and those who
started treatment on menstrual cycle day 3 (Table 1). The
number of oocytes retrieved in patients who were treated
with corifollitropin alfa on menstrual cycle day 2 or day 3
was similar. In the rFSH arm, a similar number of oocytes
retrieved was also observed in patients who started treat-
ment on menstrual cycle day 2 or day 3. Cycle cancel-
lation rates were higher in the corifollitropin alfa arm than
the rFSH arm. The ongoing pregnancy rates for patients
who started treatment on cycle days 2 or 3 were 37.9%
and 43.5% in the corifollitropin alfa arm and 35.1% and
43.1% in the rFSH arm, respectively (Figure 1). The
estimated difference (95% CI) in ongoing pregnancy rate
between cycle day 2 and cycle day 3 adjusted for region,
treatment group, age, and treatment flexibility options (ii)
and (iii) was -4.3% (-4.3 percentage points) (95% CI: -9.4%,
0.8%) (Table 2). The estimated difference was -6.8%
(-11.9%, 1.7%) when adjusted for treatment group only
and -4.9% (-10.0%, 0.1%) when adjusted for treatment
group, age, and region (data not shown).
hCG administered on the day the hCG criterion was reached
or 1 day later
In both the corifollitropin alfa arm and the rFSH arm,
the number of oocytes retrieved was similar for patients
who received hCG when the criterion was reached and
for patients with a 1-day delay in hCG administration
(Table 3). Cycle cancellation rates were higher in the
corifollitropin alfa arm compared with the rFSH arm in
patients who received hCG on the day the hCG criterion
was met. The ongoing pregnancy rates for patients with
hCG administration on the day the criterion was
reached and for those with a 1-day delay were 40.7% and
Table 1 Ovarian response and clinical outcomes: start treatment on cycle day 2 or cycle day 3 (Analysis Set 1)
Corifollitropin alfa rFSH
Day 2 Day 3 Day 2 Day 3
n = 343 n = 368 n = 353 n = 364
Duration of stimulation, days, mean (SD) 9.8 (1.4) 9.4 (1.5) 9.4 (1.2) 9.0 (1.3)
Follicles on day 8 ≥11 mm, mean (SD) 12.0 (6.1) 13.4 (6.4) 11.4 (5.7) 11.4 (5.8)
Serum E2 on day 8, pmol/l, median (P5, P95) 2562 3285 2743 3274
(837, 7524) (840, 8918) (987, 7487) (1068, 8184)
Follicles on day of hCG ≥11 mm, mean (SD) 15.6 (6.5) 16.1 (6.9) 14.1 (6.0) 13.3 (5.8)
E2 on day of hCG, pmol/l, median (P5, P95) 4239 4899 4110 4808
(1512, 11,891) (1762, 11,671) (1501, 9762) (1740, 10,129)
No. of oocytes retrieved, mean (SD) 14.1 (8.1) 14.0 (7.9) 12.8 (6.6) 12.4 (6.5)
No. of embryos obtained on day 3, mean (SD) 8.2 (5.6) 8.3 (5.4) 7.5 (4.8) 7.4 (4.6)
No. of GQEs obtained on day 3, mean (SD) 4.5 (4.2) 4.6 (4.4) 4.4 (3.8) 4.4 (3.8)
No. of GQEs transferred, mean (SD) 1.2 (0.8) 1.3 (0.8) 1.3 (0.8) 1.4 (0.8)
Cycle cancellation rate, n (%) 24 (7.0) 34 (9.2) 19 (5.4) 17 (4.7)
SD standard deviation, P5 5th percentile, P95 95th percentile, E2 estradiol, GQEs good-quality embryos.
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42.9% in the rFSH group, respectively (Figure 1). The
estimated difference (95% CI) in ongoing pregnancy rate
between patients who received hCG when the criterion
was reached and those with a 1-day delay was 1.8%
(-4.1%, 7.6%) when adjusted for region, treatment group,
age, and treatment flexibility options (i) and (iii)
(Table 2). The estimated difference ratio was -2.0%
(-7.8%, 3.8%) when adjusted for treatment group only
and 2.0% (-3.8%, 7.8%) when adjusted for treatment
group, age, and region (data not shown).
rFSH on the day of hCG administration or not
Patients who received rFSH on the day of hCG
compared with those who did not had a slightly higher
number of oocytes retrieved in the corifollitropin arm
and a similar number of oocytes retrieved in the rFSH
arm (Table 4). Cycle cancellation rates were higher in
the corifollitropin alfa arm than the rFSH arm. The on-
going pregnancy rates for patients who received rFSHFigure 1 Ongoing pregnancy rates and 95% CIs for the different treaon the day of hCG and for those who did not were
43.1% and 36.4% in the corifollitropin alfa arm and
39.7% and 37.6% in the rFSH arm, respectively (Figure 1).
The estimated difference (95% CI) in ongoing pregnancy
rate between patients receiving rFSH on day of hCG and
those who did not was 3.2% (-2.1%, 8.6%) when adjusted
for region, treatment group, age, and treatment flexibil-
ity options (i) and (ii) (Table 2). The estimated difference
ratio was 4.3% (-1.0%, 9.6%) when adjusted for treatment
group only and 3.0% (-2.2%, 8.2%) when adjusted for
treatment group, age, and region (data not shown).
There were no substantial differences among subgroups
with respect to the incidence of OHSS (data not shown).
Step-down or fixed-dose rFSH
In both the corifollitropin alfa and rFSH treatment
groups, patients who received a reduced (step-down)
rFSH dose (<200 IU) from day 8 had numerically higher
estradiol levels on day 8 and on the day of hCG, more
follicles ≥11 mm on the day of hCG, and more oocytestment conditions.
Table 2 Estimated effect in percentage points (Δ) and associated 95% confidence interval (95% CI) of the covariates
included in Model 1 and Model 2 on ongoing pregnancy rate
Factors included
in model
Categories Model 1* Model 2†
Δ (95% CI) Δ (95% CI)
Start treatment Day 2 versus day 3 -4.3 (-9.4, 0.8)
hCG delay No delay versus 1-day delay 1.8 (-4.1, 7.6)
rFSH on day of hCG Yes versus no 3.2 (-2.1, 8.6)
rFSH from day 8 Step-down versus fixed dose -5.8 (-13.0, 1.4)
Treatment group Corifollitropin alfa versus rFSH 1.1 (-4.0, 6.2) 1.1 (-4.8, 6.9)
Age Per year increase -1.1 (-1.9, -0.3) -0.9 (-1.8, 0.0)
Region North America versus Europe 15.5 (10.2, 20.7) 12.6 (6.8, 18.5)
*Model 1 is based on Analysis Set 1, i.e., all patients who received hCG and for whom no rFSH dose was withheld for one or more consecutive days including the
day of hCG.
†Model 2 is based on Analysis Set 2, i.e., all patients who received hCG on or after day 9 and for whom no rFSH dose was withheld for one or more consecutive
days from day 8 including the day of hCG.
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rFSH (200 IU) from day 8 (Table 5). Cycle cancellation
rates were higher in the corifollitropin alfa arm than the
rFSH arm. The ongoing pregnancy rates for patients
who received rFSH step-down or fixed-dose rFSH from
day 8 were 37.0% and 40.6% in the corifollitropin alfa
arm and 31.6% and 40.7% in the rFSH arm, respect-
ively (Figure 1). The estimated difference (95% CI) in
ongoing pregnancy rate between step-down and fixed-
dose was -5.8% (-13.0%, 1.4%) when adjusted for
treatment group, age, and region (Table 2).
Corifollitropin alfa or rFSH treatment regimen
The ongoing pregnancy rate was similar in the two treat-
ment groups: the estimated treatment effect (corifol-
litropin alfa - rFSH) was around 1% in both models





Duration of stimulation, days, mean (SD) 9.4 (1.4)
Follicles on day 8 ≥11 mm, mean (SD) 12.8 (6.6)
Serum E2 on day 8, pmol/l, median (P5, P95) 3019
(837, 8588)
Follicles on day of hCG ≥11 mm, mean (SD) 16.0 (6.9)
E2 on day of hCG, pmol/l, median (P5, P95) 4551
(1629, 11,450)
No. of oocytes retrieved, mean (SD) 14.2 (8.3)
No. of embryos obtained on day 3, mean (SD) 8.1 (5.7)
No. of GQEs obtained on day 3, mean (SD) 4.4 (4.3)
No. of GQEs transferred, mean (SD) 1.2 (0.8)
Cycle cancellation rate, n (%) 45 (9.1)
SD standard deviation, P5 5th percentile, P95 95th percentile, E2 estradiol, GQEs goooptions, its interaction with treatment group was tested




The results of this post hoc analysis show that reducing
the daily dose of rFSH from stimulation day 8 onward in
a corifollitropin alfa or rFSH treatment regimen offers
the flexibility to individualize care, and delaying the day
of hCG administration does not compromise ongoing
pregnancy rates. Treatment flexibility when starting ova-
rian stimulation was shown to have no statistically
significant effect on clinical outcome in patients treated
with corifollitropin alfa or rFSH in a GnRH antagonist
protocol, but the pregnancy rate was estimated to be
4.3% lower in patients starting treatment on menstrualas soon as criterion was reached or 1-day delay
tropin alfa rFSH
Delay No delay Delay
n = 188 n = 516 n = 191
9.9 (1.3) 9.1 (1.3) 9.5 (1.0)
12.8 (5.5) 11.4 (5.9) 11.5 (5.1)
2753 2965 3097
(1013, 7634) (1017, 8184) (1046, 7450)
15.6 (5.5) 13.8 (6.2) 13.6 (5.0)
4881 4477 4331
(1883, 11,964) (1718, 9872) (1758, 10,349)
14.1 (6.7) 12.4 (6.6) 13.3 (6.3)
8.9 (4.9) 7.4 (4.7) 7.8 (4.5)
5.4 (4.2) 4.3 (3.7) 4.8 (3.9)
1.4 (0.7) 1.3 (0.8) 1.3 (0.8)
10 (5.3) 23 (4.5) 10 (5.2)
d-quality embryos.
Table 4 Ovarian response and clinical outcomes: received rFSH on day of hCG or did not (Analysis Set 1)
Corifollitropin alfa rFSH
No Yes No Yes
n = 247 n = 469 n = 255 n = 466
Duration of stimulation, days, mean (SD) 9.6 (1.3) 9.6 (1.5) 9.3 (1.3) 9.1 (1.2)
Follicles on day 8 ≥11 mm, mean (SD) 13.4 (6.0) 12.3 (6.5) 11.1 (5.1) 11.5 (6.0)
Serum E2 on day 8, pmol/l, median (P5, P95) 3382 2697 3075 2938
(1039, 8441) (793, 8147) (1057, 9432) (995, 7854)
Follicles on day of hCG ≥11 mm, mean (SD) 16.7 (6.5) 15.3 (6.7) 13.6 (5.7) 13.8 (6.1)
E2 on day of hCG, pmol/l, median (P5, P95) 5468 4221 4514 4331
(1982, 12,038) (1497, 11,120) (1736, 10,349) (1600, 9799)
No. of oocytes retrieved, mean (SD) 14.8 (8.1) 13.6 (7.8) 12.4 (6.2) 12.7 (6.7)
No. of embryos obtained on day 3, mean (SD) 8.5 (5.4) 8.1 (5.5) 7.3 (4.4) 7.5 (4.8)
No. of GQEs obtained on day 3, mean (SD) 4.7 (4.1) 4.5 (4.4) 4.4 (3.5) 4.4 (3.9)
No. of GQEs transferred, mean (SD) 1.2 (0.8) 1.3 (0.8) 1.3 (0.8) 1.3 (0.7)
Cycle cancellation rate, n (%) 22 (8.9) 36 (7.7) 12 (4.7) 24 (5.2)
SD standard deviation, P5 5th percentile, P95 95th percentile, E2 estradiol, GQEs good-quality embryos.
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rFSH step-down. Starting stimulation too early could
disturb complete shedding of the endometrium due to
an early rise in estradiol and, thus, impair receptivity [7].
Interpretation
The findings of this post hoc analysis are supported by
those of several prior studies on treatment flexibility.
With regard to a step-down or fixed dose of FSH, a
meta-analysis of 10 studies (1952 IVF cycles) comparing
a daily dose of 100 IU versus 200 IU rFSH and 150 IU
versus 200 IU rFSH or higher showed that although the
oocyte yield was greater in the >200 IU/day dose group,




Duration of stimulation, days, mean (SD) 10.0 (1.1)
Follicles on day 8 ≥11 mm, mean (SD) 15.2 (5.1)
E2 on day 8, pmol/l, median (P5, P95) 4734
(1431, 8918)
Follicles on day of hCG ≥11 mm, mean (SD) 20.5 (5.3)
Serum E2 on day of hCG, pmol/l, median (P5, P95) 7817
(2393, 13,799)
No. of oocytes retrieved, mean (SD) 19.4 (8.1)
No. of embryos obtained on day 3, mean (SD) 11.8 (6.0)
No. of GQEs obtained on day 3, mean (SD) 6.5 (5.7)
No. of GQEs transferred, mean (SD) 1.1 (0.8)
Cycle cancellation rate, n (%) 15 (10.9)
SD standard deviation, P5 5th percentile, P95 95th percentile, E2 estradiol, GQEs goothe lower dose groups. The risk of an insufficient response
to ovarian stimulation was greatest in the 100 IU/day dose
group and the risk of developing OHSS was greater in the
>200 IU/day dose group [8]. The authors concluded that
the optimal daily rFSH stimulation dose is 150 IU in pre-
sumed normal responders aged <39 years undergoing IVF.
A step-down approach for ovulation induction was also
deemed more appropriate to avoid multiple follicular
development in women with polycystic ovarian syndrome
[9]. In addition, a step-down rFSH approach was shown to
improve implantation rates and pregnancy rates in high
responders [10]. Patients in the corifollitropin alfa or rFSH
arms who received a step-down approach, in this post hoc
analysis, had higher estradiol levels on day 8 and on ther fixed dose rFSH from day 8 (Analysis Set 2)
llitropin alfa rFSH
Fixed dose Step-down Fixed dose
n = 409 n = 79 n = 430
10.1 (1.3) 9.8 (1.1) 9.8 (1.0)
10.5 (5.4) 14.1 (5.3) 9.6 (4.7)
2341 4184 2415
(738, 6019) (995, 10,606) (910, 6276)
14.1 (6.2) 18.0 (6.1) 12.6 (5.3)
4147 7212 4221
(1497, 10,239) (1655, 16,772) (1696, 9726)
12.4 (7.4) 16.5 (6.4) 11.8 (6.4)
7.5 (5.2) 10.2 (5.2) 7.1 (4.5)
4.1 (3.8) 5.5 (4.4) 4.3 (3.7)
1.3 (0.8) 1.3 (0.7) 1.3 (0.8)
30 (7.3) 4 (5.1) 23 (5.3)
d-quality embryos.
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and more oocytes retrieved than patients who received a
fixed dose. However, the decision of a step-down or fixed-
dose rFSH regimen was at the discretion of the inves-
tigator and rFSH was generally reduced in patients who
had a high ovarian response. This process reflects clinical
practice.
Administration of hCG for ovulation induction within
24 h after termination of rFSH has also been associated
with good outcomes in patients undergoing COS in
previous studies [11,12]. Delaying hCG administration
has been shown to result in a higher incidence of
endometrial advancement on the day of oocyte retrieval
in donors stimulated with rFSH and GnRH antagonists
[13]. Additionally, a large randomized controlled trial
evaluating the effect of prolonging the follicular phase
by delaying hCG administration on IVF outcome
showed that oocyte or embryo quality was not affected
in patients who received hCG as soon as the criterion
was met or 2 days later [14]; however, delaying hCG
administration was associated with a significantly lower
ongoing pregnancy rate. Similar pregnancy rates have
been reported with administration of hCG as soon as
there were three or more follicles ≥16 mm or the day
after [15]. In this post hoc analysis, it was shown that
administration of hCG on the day hCG criterion was
reached or 1 day later did not significantly affect ongoing
pregnancy rates in patients treated with corifollitropin alfa
or rFSH. However, in the current study population more
subjects with hCG delay were from IVF centers in North
America where higher ongoing pregnancy rates, compared
with Europe, have previously been reported [6]. This has
skewed the data in favor of ongoing pregnancy in the hCG
delay population as described in the Results section: the
estimated ongoing pregnancy rate difference between no
delay and 1-day delay increased from -2.0% when only
adjusted for treatment group to +2.0% when adjusted for
factors age and region as well. Administration of rFSH on
the day of hCG or no rFSH on the day of hCG also did
not affect the ongoing pregnancy rates in the corifol-
litropin alfa or rFSH arm.
Treatment flexibility on the starting day of stimulation
is often applied to avoid weekend oocyte retrievals.
Comparison of clinical outcomes has been previously
assessed in patients starting stimulation on menstrual
cycle day 2 or menstrual cycle day 5 [16]. Starting stimu-
lation on cycle day 5 resulted in more cancellations due
to insufficient response and a lower percentage of oo-
cytes retrieved than patients starting stimulation on
cycle day 2. There was no difference in the ongoing
pregnancy rates between the two groups. However, a
higher ongoing pregnancy rate was observed in patients
starting stimulation on cycle day 3, as reported in the
primary manuscript of the Engage trial [3] and in a recentretrospective analysis of patients treated with rFSH in the
Engage trial [17]. In this analysis of the Engage trial, in
which the probability of pregnancy was adjusted for fac-
tors treatment group, region, age, and treatment flexibility
options (ii) (no hCG delay versus 1-day delay) and (iii)
(rFSH administered on day of hCG or not), the estimated
day 2 minus day 3 ongoing pregnancy rate (95% CI) was -
4.3% (-9.4%, 0.8%). The estimated pregnancy rate for
starting day 2 is numerically lower than for starting day 3;
however, as the 95% CI includes zero we cannot conclude
that there is any difference.
A recent systematic review suggested that there may
be an increased risk of OHSS following treatment with
corifollitropin alfa [18]. Errors in that review have already
been pointed out by Mannaerts et al. [19]. Nonetheless, a
numerically higher risk (although not-statistically signifi-
cant) remains which is linked to the degree of ovarian
response. However, we note that it is becoming clear that
with appropriate use of a GnRH agonist trigger in
women at risk of over-response, OHSS can be largely
eliminated [20].
This post hoc analysis provides valuable insight on the
impact of “real-life” treatment flexibility on clinical out-
comes in patients treated with corifollitropin alfa or rFSH.
Limitations
As with any post hoc analysis, conclusions drawn from
the analyses in this report must be viewed with caution
because all of the comparisons were post hoc and should
be confirmed by prospective studies.
Conclusions
Treatment flexibility at the start or completion of ova-
rian stimulation does not substantially affect clinical
outcome in patients treated with corifollitropin alfa or in
those treated with daily rFSH for the first 7 days of COS
using a GnRH antagonist protocol.
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